Myeloid differentiation primary response protein 88 (MyD88) is classically known as an adaptor, linking TLR and IL-1R to downstream signaling pathways in the innate immune system. In addition to its role in innate immune cells, MyD88 has been shown to play an important role in T cells. How MyD88 regulates helper T-cell differentiation remains largely unknown, however. Here we demonstrate that MyD88 is an important regulator of IL-17-producing CD4
+ T helper cells (Th17) cell proliferation. MyD88-deficient CD4
+ T cells showed a defect in Th17 cell differentiation, but not in Th1 cell or Th2 cell differentiation. The impaired IL-17 production from MyD88-deficient CD4 + T cells is not a result of defective RAR-related orphan receptor γt (RORγt) expression. Instead, MyD88 is essential for sustaining the mammalian target of rapamycin (mTOR) activation necessary to promote Th17 cell proliferation by linking IL-1 and IL-23 signaling. MyD88-deficient CD4 + T cells showed impaired mTOR activation and, consequently, reduced Th17 cell proliferation. Importantly, the absence of MyD88 in T cells ameliorated disease in the experimental autoimmune encephalomyelitis model. Taken together, our results demonstrate that MyD88 has a dual function in Th17 cells by delivering IL-1 signaling during the early differentiation stage and integrating IL-23 signaling to the mTOR complex to expand committed Th17 cells. M yeloid differentiation primary response protein 88 (MyD88) was originally isolated as a cloned cDNA that was induced in M1 myeloblastic leukemia cells on activation with IL-6 (1). The function of MyD88 was then uncovered, because the C-terminal portion of MyD88 was found to be similar to the Drosophila Toll receptor and the mammalian IL-1 receptor (IL-1R) (2) . This conserved region in the cytoplasmic tails of IL-1R and Toll-like receptor (TLR) is referred to as the Toll/IL-1R (TIR) domain. MyD88 is now known to play an essential role in the innate immune response by linking members of the TLR and IL-1R superfamily to the downstream activation of NF-κB and MAPKs (3) .
Among cytokines produced by activated innate immune cells, IL-23 has been shown to promote production of the proinflammatory cytokine IL-17 in activated T cells (4) . IL-17-producing CD4 + T helper (Th17) cells were identified after the discovery that IL-23 is linked to traditionally Th1-associated autoimmune disorders, such as experimental autoimmune encephalitis (EAE).
Il23a
−/− mice, but not Il12a −/− mice, were shown to be autoimmune-resistant (5) . IL-23 is required for Th17 cell-mediated autoimmune disorders in vivo, but the role of IL-23 in Th17 cell differentiation remains controversial (6) . Previous studies support the idea that IL-23 helps expand or maintain Th17 cells (7) (8) (9) . In addition, a recent study reemphasized the importance of IL-23 in the generation of pathogenic Th17 cells, showing that they can be generated with IL-23, IL-6, and IL-1β (10) .
In addition to IL-23, other cytokines, including TGF-β, IL-6, and IL-1, play roles in Th17 cell development. TGF-β with proinflammatory cytokines was shown to be critical in the support of Th17 cell differentiation (8, 11, 12) . In particular, an inflammatory cytokine, IL-6, favors Th17 cell development by inhibiting regulatory T cells (13) . The role of IL-1 in Th17 cell differentiation has been investigated as well. IL-1 receptor type 1-deficient (Il1r1 −/− ) mice showed a lower incidence of EAE and severe defects in the induction of IL-17-producing T cells (14) . IL-1 signaling in T cells was further shown to be involved in early Th17 cell differentiation by regulating IFN regulatory factor 4 and RAR-related orphan receptor γt (RORγt) (15) .
Although roles for MyD88 in the innate immune system are well established, little is known about their potential function in the adaptive immune system. Several studies have demonstrated important roles of MyD88 in T cells. For instance, T-cell expression of MyD88 is required for resistance to Toxoplasma gondii (16); the MyD88-dependent signaling pathway in CD4 + T cells has been shown to enhance proliferation and augment humoral immune responses (17) ; and MyD88 is required for Tcell effector function in the development of inflammatory bowel disease (18) . Interestingly, although Myd88 −/− T cells were found to exhibit decreased IL-17 production (18), how T-cell differentiation could be regulated by MyD88 was not clear in that study.
Here we investigated the molecular mechanism by which MyD88 regulates CD4 + T-cell differentiation. Our results demonstrate that MyD88 contributes to Th17 cell differentiation, but not to Th1 or Th2 cell differentiation. Both IL-1 and IL-23 signaling depend on MyD88 and result in up-regulation of IL-23R. MyD88-deficient Th17 cells show reduced IL-23R expression and mTOR activation, leading to impaired Th17 cell proliferation. Furthermore, MyD88 is crucial for proper Th17 cell differentiation in vivo. Thus, our findings reveal a unique role for the innate adaptor MyD88 in the regulation of Th17 cell differentiation.
Results
Impaired IL-17A Production in MyD88-Deficient CD4 has been unclear. To study how MyD88 regulates Th17 cell differentiation, we enriched CD4 + T cells from MyD88-sufficient (i.e., WT) and Myd88 −/− mice and performed in vitro T-cell differentiation. The Myd88 −/− CD4 + T cells showed a substantial defect in IL-17A production under Th17 cell-polarizing conditions (Fig. 1A) . MyD88 deficiency did not affect IFN-γ production under Th1 cell-polarizing conditions or IL-4 production under Th2 cell-polarizing conditions (Fig. 1A) .
Given our observation of impaired IL-17A production after T-cell restimulation, we next asked whether the defect started during T-cell differentiation. Myd88 −/− CD4 + T cells already showed a lower frequency of IL-17A + cells after 3 d of Th17 cell differentiation (Fig. S1A) , although the defect was less dramatic than that observed after restimulation. Again, Myd88
−/− CD4 + T cells showed no defect in IFN-γ expression under Th1 cell-polarizing conditions (Fig. S1A) . In addition, the induction of Il17a mRNA was poorer in Myd88 −/− CD4 + T cells compared with WT under Th17 cell-polarizing conditions; however, Ifng mRNA levels were comparable in WT and Myd88 −/− CD4 + T cells (Fig. S1B ). Along with IL-17A, the production of IL-17F, another IL-17 cytokine family member, was severely impaired from Myd88 −/− CD4 + T cells after restimulation, and the defect in Il17f mRNA level was detected based on the early Th17 cell differentiation (Fig. S1C ).
RORγt Is Expressed Normally in Myd88
−/− Th17 Cells. IL-2 or IL-10 signaling has been shown to modulate Th17 cell generation (19, 20) ; however, in the present study, impaired IL-17 production in Myd88 −/− CD4 + T cells was not related to increased IL-2 or IL-10 production (Fig. S2 ). Given that Myd88
−/− CD4 + T cells are defective in IL-17 production under Th17 cell-polarizing conditions but not in IFN-γ or IL-4 production under Th1 or Th2 cell-polarizing conditions, respectively, we speculated that the defect might result from cytokine signaling specific to Th17 cell differentiation. Among Th17-skewing cytokines, including TGF-β, IL-6, IL-1β, and IL-23, we first focused on IL-1β because of the well-established role of MyD88 as an adaptor in IL-1R signaling (3) . Indeed, the defect in IL-17A production from Myd88 −/−
CD4
+ T cells was less marked in the absence of IL-1β (Fig. S3A) . However, the defect could not be explained solely by the lack of IL-1 signaling in Myd88 −/− CD4 + T cells, because they still exhibited impaired IL-17A production without IL-1β (Fig. S3A) . A similar defect in Il17a mRNA expression from Myd88 −/−
+ T cells was observed in the absence of IL-1β (Fig. S3B ). We then investigated whether TGF-β signaling was altered in Myd88 −/− CD4 + T cells by assessing Foxp3 expression as a readout.
Compared with WT, Myd88
−/− CD4 + T cells expressed more Foxp3 after treatment with TGF-β alone (Fig. 1B, Upper) . TGF-β-induced Foxp3 has been shown to inhibit Th17 cell differentiation by antagonizing RORγt (21) . Thus, we evaluated whether enhanced TGF-β-induced Foxp3 expression in
After cells were cultured with various cytokines, both WT and Myd88 −/− CD4 + T cells showed greatly reduced Foxp3 expression under IL-17-producing conditions (TGF-β + IL-6 or TGF-β + IL-6 + IL-1β + IL-23) (Fig. 1B) . Importantly, under Th17-polarizing conditions, Myd88
−/− CD4 + T cells showed no significant decrease in Rorc mRNA levels (Fig. S4 ) or RORγt expression (Fig.  1C) . These data suggest that impaired IL-17 production from Myd88 −/− CD4 + T cells is not related to reduced RORγt expression.
IL-1β and IL-23 Contribute Synergistically to IL-17 Production. Because we observed the greatest impairment in IL-17 production from Myd88 −/− CD4 + T cells after anti-CD3 restimulation (Fig.  1A) , we investigated T-cell responses during the later differentiation stage. At 5 d after Th17 cell-polarizing cultures, cells were restimulated with anti-CD3 for 6 h to assess mRNA levels of cytokines. Consistent with our results presented above, genes for IL-17 cytokine family members IL-17A, IL-17F, and IL-22 were poorly expressed from Myd88 −/− CD4 + T cells after anti-CD3 restimulation ( Fig. 2A) . Importantly, Myd88
−/− CD4 + T cells did not exhibit a global defect in cytokine expression; IL-21, IL-2, and IL-10 expression was actually enhanced ( Fig. 2A ). Of note, on day 5 (0 h), mRNA levels of IL-17A, IL-17F, and IL-22 were increased in WT, but not in Myd88 −/− , CD4 + T cells ( Fig. 2A ). This finding prompted us to examine the later stage of Th17 cell differentiation in depth.
IL-17A production was further increased at day 5 in WT, but not in Myd88 −/− CD4 + T cells, when the differentiation was driven by IL-6, TGF-β, IL-1β, and IL-23 ( Fig. 2B ). The increase in IL-17A production during day 3-5 in WT was not observed without IL-1β and IL-23, suggesting a critical role of IL-1β-and IL-23-mediated signaling. At day 5, the amount of Il17a mRNA in WT was increased when both IL-1β and IL-23 were added together with TGF-β and IL-6 in the culture (Fig. 2C ). Similarly (albeit with different kinetics), Il17f gene expression was maintained in the presence of IL-1β and IL-23 together with TGF-β and IL-6 (Fig. 2C) .
Along with Rorc, several transcription factors or molecules, including Ahr (22), Batf (23), Socs3 (24), Runx1 (25), Rora (26), and Il23r (13), are known to be involved in Th17 cell differentiation. We tested whether the impairment of IL-17 expression in Myd88 −/− CD4 + T cells by IL-1β and IL-23 is caused by differential expression of these factors. The expression of Ahr, Batf, and Socs3 mRNA was comparable in WT and Myd88 −/− CD4 + T cells (Fig. 2D ). The expression of Runx1 and Rora mRNA did not differ with or without IL-1β and IL-23; however, Il23r expression was greatly increased at day 5 in WT, but not in Myd88
+ T cells by IL-1β and IL-23 ( Fig. 2D ).
MyD88-Dependent IL-23R Expression Enhances IL-17A Production. We then examined whether IL-23R-mediated signaling requires MyD88 for Th17 cell differentiation. Unlike WT CD4 + T cells, which showed a synergistic effect on Il17a expression by IL-1β and IL-23, Myd88
−/− CD4 + T cells failed to demonstrate the same effect even with various combinations of IL-1β and IL-23 (Fig. 3A, Left) . In parallel studies, Il23r expression was lower from Myd88 −/− CD4 + T cells compared with WT, suggesting a potential role of MyD88 in the induction of IL-23R (Fig. 3A, Right) .
If ation and diminished after 3 d of culture ( Fig. 4A and Fig. S5 ). Myd88 −/− CD4 + T cells exhibited no defect in Il1r1 expression; in contrast, Il23r expression was low until day 3 and increased during later Th17 cell differentiation, which was not observed in Myd88 −/− CD4 + T cells (Fig. 4A ). Because these two receptors were expressed during different time periods, we asked whether IL-1 signaling and IL-23 signaling are sequentially involved in Th17 cell differentiation. To test this, we added IL-1β or IL-23 to the cultures at different time points. When IL-1 signaling was absent during early Th17 cell development, Il17a and Il23r expression was poorly induced (Fig. 4B) . Notably, when cells were initially cultured with TGF-β, IL-6, and IL-1β, adding IL-23 at day 3 potently induced Il17a and Il23r expression, similar to when all cytokines were added at the beginning ( Fig. 4B ; compare the fifth and seventh groups). Taken together, these results indicate that IL-1 signaling is essential during early Th17 cell development, and that IL-23 is required mainly for later Th17 cell differentiation.
We next asked which signaling molecules are involved in the later Th17 cell differentiation. To test this, we added specific inhibitors for mTOR, IKK, JNK, and p38 at day 3 of Th17 cultures and assessed Il17a expression at day 5. Our results show that blocking NF-κB or MAPK signaling had little effect on Il17a expression (Fig. 4C) . However, rapamycin treatment reduced Il17a expression, suggesting that the mammalian target of rapamycin (mTOR)-mediated signaling pathway is critical for the later Th17 cell differentiation. Moreover, Il23r expression was reduced by rapamycin treatment (Fig. S6) . In fact, phosphorylation of S6 ribosomal protein was sustained in WT at day 5 when IL-1β and IL-23 were present together with IL-6 and TGF-β (Fig. 4D) . Furthermore, both IL-1β and IL-23 are required for activation of the mTOR signaling pathway (Fig. 4E) . Because mTOR activation is linked to cell proliferation, we assessed whether IL-1 and IL-23 signaling promotes cell proliferation. WT and Myd88
−/− CD4 + T cells proliferated at a similar rate during early stages of Th0 or Th17 cell differentiation (Fig. S7) . However, during later Th17 cell differentiation (day 3-5), MyD88-dependent IL-1β and IL-23 signaling was required for the cell proliferation (Fig. 4F) . Taken together, these findings indicate that MyD88 plays a critical role in integrating IL-1 and IL-23 signaling for Th17 cell proliferation and expansion. (27) were cultured initially with TGF-β, IL-6, and IL-1β. To avoid hindrance of early IL-1 signaling, 4-OHT was added at day 2, followed by IL-23 at day 3. As shown in previously (Fig. 4B) The whole-cell lysates were prepared on day 3 or day 5. P-S6, S6, and GAPDH were detected by immunoblot analysis. (E) Cells were activated and cultured with the indicated cytokines. At day 5, the whole-cell lysates were prepared. P-mTOR, P-S6K, P-S6, and β-actin were detected by immunoblot analysis. (F) Cells were activated and cultured with the indicated cytokines for 3 d. At the end of day 3, cells were washed, labeled with carboxyfluorescein diacetate succinimidyl ester, and cultured in T-cell medium for additional 3 d in the presence of same cytokines. Carboxyfluorescein diacetate succinimidyl ester dilution and IL-17A expression were analyzed by flow cytometry. Results are representative of two independent experiments (A and E) or three independent experiments (B, C, D, and F).
production in WT, but not in Myd88
+ T cells (Fig. 5B) . Importantly, in the presence of 4-OHT, IL-17A production from Myd88 fl/fl ERCreT2 CD4 + T cells was significantly reduced compared with WT ( Fig. 5 B and C) . mRNA expression of Il17a and Il23r genes was also poorly induced in Myd88 fl/fl ERCreT2 CD4 + T cells compared with WT (Fig. 5D ). In addition, MyD88-dependent IL-23 signaling was required for activation of mTOR signaling pathway (Fig. S8) . Taken together, these results indicate that MyD88 is an important regulator not only of early IL-1, but also of later IL-23 signaling for Th17 cell proliferation.
MyD88 Is Crucial for Th17 Cell Differentiation in Vivo. To determine whether the proposed role for MyD88 in Th17 cell differentiation is relevant in vivo, EAE was induced in WT and Myd88ΔT mice. All WT mice (16 of 16) developed EAE after immunization with myelin oligodendrocyte glycoprotein (MOG), compared with only 6 of 13 Myd88ΔT mice (Table S1 ). EAE was less prevalent in Myd88ΔT mice compared with WT mice (Fig. 5E) ; however, the disease was of similar onset and severity in the two groups (Table S1 ). Taken together, these data demonstrate that MyD88 has a crucial role for proper Th17 cell differentiation in vivo.
Discussion
Many molecules classically known to be critical for the innate immune system also have important functions in adaptive immune responses (28, 29) . The present study shows that MyD88 plays an important role in Th17 cell differentiation. In addition, it demonstrates the underlying molecular mechanism by which MyD88-mediated IL-1 signaling sequentially synergizes with IL-23 to promote Th17 cell proliferation.
IL-23 has a unique function in the maintenance of a T-cell subset producing IL-17 (6). IL-23R was shown to be essential for the terminal differentiation of Th17 cells in vivo (9); however, the molecular mechanism governing expression of the IL-23R remains unclear. IL-23R expression was abolished in the absence of Th17-inducing proinflammatory cytokines such as IL-6 (13). Importantly, it has been suggested that IL-23 induces IL-23R expression via positive feedback regulation (30, 31) . Our results further show that MyD88-mediated IL-1 signaling in CD4 + T cells is a prerequisite for the up-regulation of IL-23R by IL-23. IL-1 and IL-23 are produced mainly by activated antigen-presenting cells. Of interest, IL-1 also up-regulates IL-23 subunit p19 gene expression in antigen-presenting cells (32) . Thus, IL-1 and IL-23 signaling seems to be closely regulated through MyD88 in both innate and adaptive immune cells.
IL-1 signaling on T cells is known to be important (14, 15). The incidence of EAE is significantly lower in Il1r1
−/− mice compared with WT mice, correlated with a failure to induce Th17 cells (14) . The molecular mechanism by which IL-1R contributes to Th17 cell differentiation remains unclear, however. Chung et al. (15) reported that IL-1 signaling is required for early Th17 cell differentiation by up-regulating RORγt and IFN regulatory factor 4 expression; however, as shown in the present study, RORγt expression is not altered in Myd88 There is growing interest in the interplay between host metabolism and the immune system. In particular, mTOR plays an essential role in integrating environmental cues. Several previous studies have shown that mTOR critically regulates the differentiation of T cells (37) (38) (39) (40) . mTOR in T cells acts to integrate signal 1 (antigen recognition through T-cell receptor) and signal 2, the integrated sum of environmental cues, including CD28, IL-2R, amino acids. and skewing cytokines (41) . In the present study, Myd88 not integrate IL-1 and IL-23 signaling (signal 2) and failed to generate sustained mTOR activation. This may explain why MyD88 deficiency affects only IL-17 expression, even though mTORC1 was shown to be involved in both Th1 and Th17 responses (40) .
In conclusion, our findings show that MyD88 has a dual function in Th17 cell differentiation. MyD88 delivers IL-1 signaling during the initial commitment stage and links it to IL-23 signaling, which expands committed Th17 cells via mTOR activation. Given that MyD88 also plays an important role in activating innate immune responses, MyD88 serves as a good example linking two arms of the immune systems. Our results have important implications for targeting MyD88-dependent signaling in both innate and adaptive immune cells to treat Th17 cell-associated diseases.
Materials and Methods

Myd88-deficient, Myd88
flox/flox , Myd88 fl/fl CreT2 mice have been described previously (1) . The mice were housed in a conventional pathogen-free facility at Beth Israel Deaconess Medical Center. All animal procedures were approved by each institution's Committee on the Use and Care of Animals.
Antibodies and Reagents. Antibodies used for flow cytometry included anti-IL-17A (TC11-18H10), anti-IFN-γ (XMG1.2), anti-IL-4 (11B11), anti-CD4 (RM4-5), anti-CD69 (H1.2F3), anti-CD132 (4G3), anti-CD25 (PC61), anti-CD44 (IM7), anti-CD62L (MEL-14), anti-CD45RB (16A), anti-CD90.1 (Thy1.1, OX-7), and anti-CD271 (NGFR; C40-1457) (all from BD Biosciences). The Foxp3 Fixation/Permeabilization Kit and anti-RAR-related orphan receptor γt (RORγt) (AFKJS-9) and anti-Foxp3 (FJK-16s) antibodies were purchased from eBioscience. Anti-CD3 (2C11), anti-CD28 (37.51), anti-CD16/CD32 (2.4G2), neutralizing anti-IFN-γ (XMG1.2), and anti-IL-4 (11B11) were purified from hybridoma supernatants. Anti-IL-2 and anti-IL-10 were purchased from BioLegend. IL-12, IL-4, IL-6, TGF-β, IL-1β, and IL-23 were purchased from Peprotech. Plat E cells were purchased from Cell Biolabs. Rapamycin, SB202190, BMS-345541, and SP600125 were purchased from Calbiochem, and 4-hydroxytamoxifen (4-OHT) was purchased from Sigma-Aldrich. Paired cytokine-specific ELISA antibodies were obtained from R&D Systems or eBioscience. Antibodies used for immunoblot analysis included phospho-mTOR (Ser2448), phospho-p70 S6 kinase (Thr389), phospho-S6 ribosomal protein (Ser240/244), S6 ribosomal protein (5G10), phospho-Stat3 (Tyr705), Stat3, MyD88 (all from Cell Signaling Technology), GAPDH (6C5; from Abcam), and β-actin (from Sigma-Aldrich).
Cell Culture and T-Cell Differentiation in Vitro. Spleens and lymph nodes were isolated from Myd88 −/− and C57BL/6 mice, and total CD4 + T cells or CD4 + CD62L + T cells were purified using MACS beads (Miltenyi Biotec). Cells were grown in complete culture medium composed of RPMI supplemented with 10% (vol/vol) FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, 2 mM glutamine, 10 mM Hepes, 1 nM sodium pyruvate, and 55 μM β-mercaptoethanol. Then 0.7 × 10 6 cells/well were activated by plate-bound anti-CD3 (5 μg/mL) and soluble anti-CD28 (1 μg/ mL) on 48-well tissue culture plates. The skewing conditions for different T-cell subsets were as follows: 10 μg/mL anti-IFN-γ and 10 μg/mL anti-IL-4 for Th0, 10 ng/mL IL-12 and 10 μg/mL anti-IL-4 for Th1, 10 ng/mL IL-4 and 10 μg/mL anti-IFN-γ for Th2, 5 ng/mL TGF-β, 50 ng/mL IL-6, 10 ng/mL IL-1β, 20 ng/mL IL-23, 10 μg/mL anti-IFN-γ, and 10 μg/mL anti-IL-4 for Th17.
Flow Cytometry. For intracellular staining, cells from culture were restimulated with 50 ng/mL phorbol 12-myristate 13-acetate (Sigma-Aldrich), 500 ng/mL ionomycin (Sigma-Aldrich) and GolgiPlug (BD Biosciences) for 4 h at 37°C. Cells were then incubated with anti-CD16/CD32 for 15 min at 4°C to block nonspecific antibody binding, and stained for appropriate surface markers for 20 min at 4°C. Cells were fixed and permeabilized, followed by intracellular cytokine staining. For Foxp3 and RORγt staining, cells were harvested without phorbol 12-myristate 13-acetate/ionomycin restimulationm using the Foxp3 Fixation/Permeabilization Kit according to the manufacturer's instructions. For carboxyfluorescein diacetate succinimidyl ester (CFSE) labeling, naive (at day 0 culture) or activated (at the end of day 3 culture) T cells were washed twice with PBS/0.1% BSA and labeled with the CellTrace CFSE Cell Proliferation Kit (Invitrogen) according to the manufacturer's instructions. Events were acquired on a FACSCanto (BD Biosciences), and data were analyzed using FlowJo software (TreeStar). . MyD88-dependent IL-23 signaling is required for mTOR activation. CD4 + T cells were activated and cultured initially with TGF-β + IL-6 + IL-1β. Then 1 μM 4-OHT was added to the cultures at day 2, and 20 ng/mL IL-23 was added into the indicated culture at day 3. On day 5, the whole-cell lysates were prepared, and P-S6, β-actin, and MyD88 were detected by immunoblot analysis. Data are expressed as mean ± SEM.
